These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 16934134)

  • 1. Timing of drotrecogin alfa (activated) treatment in severe sepsis.
    Choi G; de Pont AC; Schultz MJ
    Crit Care; 2006; 10(4):419; author reply 419. PubMed ID: 16934134
    [No Abstract]   [Full Text] [Related]  

  • 2. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
    Micek ST; Isakow W; Shannon W; Kollef MH
    Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.
    Fry DE; Beilman G; Johnson S; Williams MD; Rodman G; Booth FV; Bates BM; McCollam JS; Lowry SF;
    Surg Infect (Larchmt); 2004; 5(3):253-9. PubMed ID: 15684796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current issues regarding the use of drotrecogin alfa (activated).
    Hassan E; Mann HJ
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):206S-215S. PubMed ID: 12492227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Solid-organ transplant recipients treated with drotrecogin alfa (activated) for severe sepsis.
    Kulkarni S; Naureckas E; Cronin DC
    Transplantation; 2003 Mar; 75(6):899-901. PubMed ID: 12660522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.
    Macias WL; Dhainaut JF; Yan SC; Helterbrand JD; Seger M; Johnson G; Small DS
    Clin Pharmacol Ther; 2002 Oct; 72(4):391-402. PubMed ID: 12386641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to optimize drotrecogin alfa (activated) use: guidelines and therapeutic controversies.
    Cohen H; Welage LS
    Pharmacotherapy; 2002 Dec; 22(12 Pt 2):223S-235S. PubMed ID: 12492229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification.
    Laterre PF; Wittebole X
    Crit Care; 2003 Dec; 7(6):445-50. PubMed ID: 14624684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drotrecogin alfa (activated) for severe sepsis.
    Maglio D
    Conn Med; 2002 Mar; 66(3):145-50. PubMed ID: 11957766
    [No Abstract]   [Full Text] [Related]  

  • 11. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.
    Dhainaut JF; Yan SB; Margolis BD; Lorente JA; Russell JA; Freebairn RC; Spapen HD; Riess H; Basson B; Johnson G; Kinasewitz GT;
    Thromb Haemost; 2003 Oct; 90(4):642-53. PubMed ID: 14515185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rise and fall of drotrecogin alfa (activated).
    Vincent JL
    Lancet Infect Dis; 2012 Sep; 12(9):649-51. PubMed ID: 22809884
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.
    Vincent JL; Angus DC; Artigas A; Kalil A; Basson BR; Jamal HH; Johnson G; Bernard GR;
    Crit Care Med; 2003 Mar; 31(3):834-40. PubMed ID: 12626993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drotrecogin alfa (activated) in the treatment of severe sepsis.
    Vincent JL
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):537-47. PubMed ID: 17009934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis.
    Barie PS; Williams MD; McCollam JS; Bates BM; Qualy RL; Lowry SF; Fry DE;
    Am J Surg; 2004 Sep; 188(3):212-20. PubMed ID: 15450822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
    Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
    Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drotrecogin alfa (activated) in sepsis: initial experience with patient selection, cost, and clinical outcomes.
    Higgins TL; Steingrub JS; Tereso GJ; Tidswell MA; McGee WT
    J Intensive Care Med; 2005; 20(6):339-45. PubMed ID: 16280407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated).
    Shorr AF; Janes JM; Artigas A; Tenhunen J; Wyncoll DL; Mercier E; Francois B; Vincent JL; Vangerow B; Heiselman D; Leishman AG; Zhu YE; Reinhart K;
    Crit Care; 2010; 14(6):R229. PubMed ID: 21176144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Titrated dose of drotrecogin alpha for liver transplant recipient.
    Saluja V; Pandey V; Pandey CK; Singhal A
    J Postgrad Med; 2012; 58(4):330-1. PubMed ID: 23298940
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of drotrecogin alfa (activated) in older patients with severe sepsis.
    Alexander SL; Ernst FR
    Pharmacotherapy; 2006 Apr; 26(4):533-8. PubMed ID: 16553513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.